Semaglutide is an FDA-approved GLP-1 receptor agonist that reduces hunger signalling, delays gastric emptying, and produces mean body weight reductions of 14.9% over 68 weeks in clinical trials
Most patients experience no downtime or significant side effects, though minor bruising or discomfort at the injection site may occur
Huge news for Peptide enthusiasts BPC-157 passed an FDA advisory panel vote and is one step closer to allowing pharmacy compounding Aside from GLP1s, this is probably the peptide that can help the most people with its efficacy in injury recovery and gut health Huge news for Peptide enthusiasts BPC-157 passed an FDA advisory panel vote and is one step closer to allowing pharmacy compounding Aside from GLP1s, this is probably the peptide that can help the most people with its efficacy in injury recovery and gut health pharmacy compounding is the unlock compounding is the real unlock, grey market BPC was always sketchy finally no more sketch sourcing Join the conversation
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics [published correction appears in Nat Rev Gastroenterol Hepatol
Avoid circumstances where your nose might get bumped
Mood and emotional well-being Some early reports and practitioner observations suggest that Dihexas effects on neural connectivity may extend to emotional resilience and mood, possibly through improved prefrontal-limbic circuit function
